Announced Date: 2024-9-30 (September 30, 2024)
Asset Name: RGT-419B(GDC-4198) and RGT-587(GDC-0587)
Licensor: Regor Pharmaceuticals (China)
Licensee (Buyer): Genentech, a member of the Roche Group
.
Asset Modality: Small Molecule
Asset Target: CDK inhibitors
Potential Indication: breast cancer
Current Stage: Phase 1
.
Scope of Authority:
Genentech will acquire Regor’s next-generation CDK inhibitors.
Genentech will be responsible for clinical development, manufacturing and commercialization worldwide.
Regor will continue to manage the two ongoing Phase 1 trials to their completion.
.
Deal Detail:
Upfront payment of $850 million,
Milestone payments, undisclosed.
.
Link:
